Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Pernille Wehn"'
Autor:
Maj-Britt Jensen, Anne-Vibeke Lænkholm, Torsten O. Nielsen, Jens Ole Eriksen, Pernille Wehn, Tressa Hood, Namratha Ram, Wesley Buckingham, Sean Ferree, Bent Ejlertsen
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophospham
Externí odkaz:
https://doaj.org/article/4673ff5f6aca4466993ba61ac60353e3
Autor:
Wesley Buckingham, Tressa Hood, Maj-Britt Jensen, Torsten O. Nielsen, Sean Ferree, Bent Ejlertsen, Jens Ole Eriksen, Namratha Ram, Pernille Wehn, Anne-Vibeke Lænkholm
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Jensen, M B, Lænkholm, A V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast Cancer Research, vol. 20, no. 1, 79 . https://doi.org/10.1186/s13058-018-1012-0
Jensen, M-B, Lænkholm, A-V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast cancer research : BCR, vol. 20, 79 . https://doi.org/10.1186/s13058-018-1012-0
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Jensen, M B, Lænkholm, A V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast Cancer Research, vol. 20, no. 1, 79 . https://doi.org/10.1186/s13058-018-1012-0
Jensen, M-B, Lænkholm, A-V, Nielsen, T O, Eriksen, J O, Wehn, P, Hood, T, Ram, N, Buckingham, W, Ferree, S & Ejlertsen, B 2018, ' The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer ', Breast cancer research : BCR, vol. 20, 79 . https://doi.org/10.1186/s13058-018-1012-0
Background: The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-base